Sagimet Biosciences (SGMT) investor relations material

Key clinical developments

• Lead FASN inhibitor, denifanstat, targets de novo lipogenesis and shows strong efficacy in moderate to severe acne and MASH, with industry-leading data from both liver and acne studies.

• Phase III acne data from China demonstrated 20% placebo-adjusted improvements in IGA and lesion count, with the FDA supporting a single phase III study in the US including adolescents aged 12-17.

• Denifanstat has a favorable safety profile, enabling rapid advancement to phase III in the US, with readout expected next year and commercial preparation underway.

• Second-generation oral FASN inhibitor will enter phase II by year-end, with dose-ranging data expected by the end of next year; a topical formulation is also in development for mild acne.

• Long-term data from Ascletis' 52-week study show continued improvement and safety, with efficacy approaching Accutane but with better tolerability.

Market and commercial strategy

• Acne market is large and underserved, with 10-15 million moderate to severe cases in the US and limited effective options; denifanstat aims to fill this gap.

• Early payer research indicates receptivity to premium pricing over current products, with gross-to-net expectations of 40-50% over time.

• Commercial launch will leverage direct-to-consumer and social media strategies, potentially reducing the need for a large sales force.

• Initial payer coverage is expected to be 25% at launch, increasing to 90% by year four, with tier placement improving over time.

• Duration of use may exceed typical antibiotics, as denifanstat allows for chronic or intermittent use with rapid response and minimal rebound.

Regulatory and trial design updates

• FDA supports a single phase III trial in the US, including adolescents, with endpoints aligned to US standards and confidence in achieving primary outcomes.

• Enrollment for the AURORA phase III trial is set to begin in October, targeting completion within six months using 55 private sites and a central IRB.

• Approval in China is anticipated by early next year, marking a significant regulatory milestone for the novel mechanism.

• Patent protection for denifanstat extends to 2037 with possible further extensions; second-generation inhibitor patents could last into the 2040s.

• Open-label extension data and further efficacy results will be presented at the European Academy of Dermatology and Venereology Congress.